R. A. Burrell, N. Mcgranahan, J. Bartek, and C. Swanton, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, vol.501, issue.7467, pp.338-383, 2013.

F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, L. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A J Clin, vol.00, issue.00, pp.1-31, 2018.

A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global Cancer Statistics: 2011, CA Cancer J Clin, vol.61, issue.2, pp.69-90, 2011.

C. J. Tabin, S. M. Bradley, C. I. Bargmann, R. A. Weinberg, A. G. Papageorge et al., Mechanism of activation of a human oncogene, Nature, vol.300, issue.5888, pp.143-152, 1982.

A. Knudson, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A, vol.68, issue.4, pp.820-823, 1971.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, vol.100, issue.1, pp.57-70, 2000.

M. Serrano, E. Gmez-lahoz, R. A. Depinho, D. Beach, and D. Bar-sagi, Inhibition of ras-induced proliferation and cellular transformation by p16, Science, vol.267, pp.249-52, 1995.

G. I. Evan, A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land et al., Induction of apoptosis in fibroblasts by c-myc protein, Cell, vol.69, issue.1, pp.119-147, 1992.

V. Armuth and I. Berenblum, Further exploration of stages in carcinogenesis, Carcinog Compr Surv, vol.7, pp.41-43, 1982.

M. J. Renan, How many mutations are required for tumorigenesis? Implications from human cancer data, Mol Carcinog, vol.7, issue.3, pp.139-185, 1993.

I. Dagogo-jack and A. T. Shaw, Tumour heterogeneity and resistance to cancer therapies, Nat Rev Clin Oncol, vol.15, issue.2, pp.81-94, 2017.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

L. Hayflick and P. S. Moorhead, The serial cultivation of human diploid cell strains, Exp Cell Res, vol.25, issue.3, pp.585-621, 1961.

A. W. Lambert, D. R. Pattabiraman, and R. A. Weinberg, Emerging biological principles of metastasis, Cell, vol.168, issue.4, pp.670-91, 2016.

O. Warburg, On respiratory impairment in cancer cells, Science, vol.124, issue.3215, pp.269-70, 1956.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011.

L. Yang, Y. Pang, and H. L. Moses, TGF-b and immune cells: an important regulatory axis in the tumor microenvironment and progression, Trends Immunol, vol.31, issue.6, pp.220-227, 2010.

S. Ostrand-rosenberg and P. Sinha, Myeloidderived suppressor cells: linking inflammation and cancer, J Immunol, vol.182, issue.8, pp.4499-506, 2009.

S. I. Grivennikov, F. R. Greten, and M. Karin, Immunity, Inflammation, and cancer, Cell, vol.140, issue.6, pp.883-99, 2010.

N. Mcgranahan, A. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.351, issue.6280, pp.1463-1472, 2016.

W. X. Zong and C. B. Thompson, Necrotic death as a cell fate, Genes Dev, vol.20, issue.1, pp.1-15, 2006.

R. D. Almeida, B. J. Manadas, A. P. Carvalho, and C. B. Duarte, Intracellular signaling mechanisms in photodynamic therapy, Biochim Biophys Acta -Rev Cancer, vol.1704, issue.2, pp.59-86, 2004.

J. Vakkila and M. T. Lotze, Tumour growth. Immunology, vol.4, pp.1-8, 2004.

I. Martincorena, K. M. Raine, M. Gerstung, K. J. Dawson, K. Haase et al., Universal patterns of selection in cancer and somatic tissues, Cell, vol.171, issue.5, 2017.

C. Magnon, S. J. Hall, J. Lin, X. Xue, L. Gerber et al., Autonomic nerve development cancer progression, Science, vol.341, issue.6142, pp.1-10, 2013.

P. Mauffrey, N. Tchitchek, V. Barroca, A. Bemelmans, V. Firlej et al., Progenitors from the central nervous system drive neurogenesis in cancer, Nature, vol.569, issue.7758, pp.672-680, 2019.
URL : https://hal.archives-ouvertes.fr/cea-02186559

C. J. Lord and A. Ashworth, The DNA damage response and cancer therapy, Nature, vol.481, issue.7381, pp.287-94, 2012.

L. B. Alexandrov, Y. S. Ju, K. Haase, P. Van-loo, I. Martincorena et al., Mutational signatures associated with tobacco smoking in human cancer, Science, vol.354, issue.6312, pp.618-640, 2016.

L. B. Alexandrov, P. H. Jones, D. C. Wedge, J. E. Sale, P. J. Campbell et al., Clock-like mutational processes in human somatic cells, Nat Genet, vol.47, issue.12, pp.1402-1409, 2015.

S. Morganella, L. B. Alexandrov, D. Glodzik, X. Zou, H. Davies et al., The topography of mutational processes in breast cancer genomes, Nat Commun, vol.7, p.11383, 2016.

S. Nik-zainal, H. Davies, J. Staaf, M. Ramakrishna, D. Glodzik et al., Landscape of somatic mutations in 560 breast cancer whole-genome sequences, Nature, vol.534, issue.7605, pp.47-54, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01388447

L. B. Alexandrov, J. Kim, N. J. Haradhvala, M. N. Huang, T. Ng et al., The repertoire of mutational signatures in human cancer, Nature, vol.578, issue.7793, pp.94-101, 2020.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, issue.7457, pp.214-222, 2013.

P. J. Campbell, G. Getz, J. M. Stuart, J. O. Korbel, and L. D. Stein, Net -ICGC/TCGA pan-cancer analysis of whole genomes. Pan-cancer analysis of whole genomes, Nature, vol.578, issue.7793, pp.82-93, 2020.

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz et al., Cancer genome landscapes, Science, vol.339, issue.6127, pp.1546-58, 2013.

Z. Sondka, S. Bamford, C. G. Cole, S. A. Ward, I. Dunham et al., The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers, Nat Rev Cancer, vol.18, issue.11, pp.696-705, 2018.

L. Génomique, paramètre limitant l'efficacité des thérapies ciblées en oncologie tome xx > n8x > xx 2020

A. Billaud, L'instabilité génomique, paramètre limitant l'efficacité des thérapies ciblées en oncologie, Bull Cancer, 2020.

F. Sanchez-vega, M. Mina, J. Armenia, W. K. Chatila, A. Luna et al., Oncogenic signaling pathways in the cancer Genome Atlas, Cell, vol.173, issue.2, 2018.

M. A. Reyna, D. Haan, M. Paczkowska, L. Verbeke, M. Vazquez et al., Pathway and network analysis of more than 2500 whole cancer genomes, Nat Commun, vol.11, issue.1, pp.1-17, 2020.

D. R. Robinson, Y. Wu, R. J. Lonigro, P. Vats, E. Cobain et al., Integrative clinical genomics of metastatic cancer, Nature, vol.548, pp.297-303, 2017.

B. B. Campbell, N. Light, D. Fabrizio, M. Zatzman, F. Fuligni et al., Comprehensive analysis of hypermutation in human cancer, Cell, vol.171, pp.1042-56, 2017.

A. Zehir, R. Benayed, R. H. Shah, A. Syed, S. Middha et al., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, vol.23, issue.6, pp.703-716, 2017.

S. F. Bakhoum and L. C. Cantley, The multifaceted role of chromosomal instability in cancer and its microenvironment, Cell, vol.174, issue.6, pp.1-27, 2018.

W. A. Flavahan, E. Gaskell, and B. E. Bernstein, Epigenetic plasticity and the hallmarks of cancer, vol.357, p.80, 2017.

P. C. Nowell, The clonal evolution of tumor cell populations, Science, vol.194, issue.4260, pp.23-31, 1976.

I. Bozic, T. Antal, H. Ohtsuki, H. Carter, D. Kim et al., Accumulation of driver and passenger mutations during tumor progression, Proc Natl Acad Sci, vol.107, issue.43, pp.18545-50, 2010.

M. Greaves and C. C. Maley, Clonal evolution in cancer, Nature, vol.481, issue.7381, pp.306-319, 2012.

C. A. Klein, Parallel progression of tumour and metastases, Nat Rev Cancer, vol.10, issue.2, p.156, 2009.

M. Gerstung, C. Jolly, I. Leshchiner, S. C. Dentro, S. Gonzalez et al., The evolutionary history of 2658 cancers, Nature, vol.578, issue.7793, pp.122-130, 2020.

Z. Hu, Z. Li, Z. Ma, and C. Curtis, Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases, Nat Genet, vol.52, issue.7, pp.701-709, 2020.

C. C. Maley, A. Aktipis, T. A. Graham, A. Sottoriva, A. M. Boddy et al., Classifying the evolutionary and ecological features of neoplasms, Nat Rev Cancer, vol.17, issue.10, pp.605-624, 2017.

J. E. Visvader, Cells of origin in cancer, Nature, vol.469, pp.314-336, 2011.

M. Jamal-hanjani, G. A. Wilson, N. Mcgranahan, N. J. Birkbak, T. Watkins et al., Tracking the evolution of non-small-cell lung cancer, N Engl J Med, vol.376, issue.22, pp.2109-2130, 2017.

Z. Hu, J. Ding, Z. Ma, R. Sun, J. A. Seoane et al., Quantitative evidence for early metastatic seeding in colorectal cancer, Nat Genet, vol.51, pp.1113-1135, 2019.

L. Ding, T. J. Ley, D. E. Larson, C. A. Miller, D. C. Koboldt et al., Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, vol.481, issue.7382, pp.506-516, 2012.

C. B. Clayman, Toxicity of primaquine in caucasians, JAMA J Am Med Assoc, vol.149, issue.17, p.1563, 1952.

A. G. Motulsky, Drug reactions, enzymes, and biochemical genetics, J Am Med Assoc, vol.165, issue.7, p.835, 1957.

U. A. Meyer, Pharmacogenetics -five decades of therapeutic lessons from genetic diversity, Nat Rev Genet, vol.5, issue.9, pp.669-76, 2004.

L. H. Hartwell, Integrating genetic approaches into the discovery of anticancer drugs, Science (80-), vol.278, issue.5340, pp.1064-1072, 1997.

C. L. Sawyers, The cancer biomarker problem, Nature, vol.452, issue.7187, pp.548-52, 2008.

L. J. Van't-veer and R. Bernards, Enabling personalized cancer medicine through analysis of gene-expression patterns, Nature, vol.452, issue.7187, pp.564-70, 2008.

C. Sawyers, Targeted cancer therapy, Nature, vol.432, issue.7015, pp.294-301, 2004.

M. Huang, A. Shen, J. Ding, and M. Geng, Molecularly targeted cancer therapy: some lessons from the past decade, Trends Pharmacol Sci, vol.35, issue.1, pp.41-50, 2014.

R. M. Hudziak, G. D. Lewis, M. Winget, B. M. Fendly, and H. M. Shepard, Ullrichlt A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol, vol.9, issue.3, pp.1165-72, 1989.

A. Quintás-cardama, H. Kantarjian, and J. Cortes, Imatinib and beyond -Exploring the full potential of targeted therapy for CML, Nat Rev Clin Oncol, vol.6, issue.9, pp.535-578, 2009.

S. G. O'brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia, N Engl J Med, vol.348, issue.11, pp.994-1004, 2003.

I. B. Weinstein, Addiction to oncogenes -the Achilles Heal of Cancer. Science (80-), vol.297, pp.64-69, 2002.

I. B. Weinstein and A. Joe, Oncogene addiction, Cancer Res, vol.68, issue.9, pp.3077-81, 2008.

S. V. Sharma, M. A. Fischbach, D. A. Haber, J. Settleman, T. Eisen et al., Oncogenic shock'': Explaining oncogene addiction through differential signal attenuation, Clinical Cancer Research, pp.4392-4397, 2006.

J. Luo, N. L. Solimini, and S. J. Elledge, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, vol.136, issue.5, pp.823-860, 2009.

W. G. Kaelin, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, vol.5, issue.9, pp.689-98, 2005.

T. Dobzhansky, Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura, Genetics, vol.31, issue.3, pp.269-90, 1946.

N. J. O'neil, M. L. Bailey, and P. Hieter, Synthetic lethality and cancer, Nat Rev Genet, vol.18, issue.10, pp.613-636, 2017.

H. Farmer, N. Mccabe, C. J. Lord, A. Tutt, D. A. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, issue.7035, pp.917-938, 2005.

H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, issue.7035, pp.913-920, 2005.

C. J. Lord, A. Tutt, and A. Ashworth, Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors, Annu Rev Med, vol.66, issue.1, pp.455-70, 2015.

A. Ashworth, C. J. Lord, and J. S. Reis-filho, Genetic interactions in cancer progression and treatment, Cell, vol.145, issue.1, pp.30-38, 2011.

M. Costanzo, B. Vandersluis, E. N. Koch, A. Baryshnikova, C. Pons et al., A global genetic interaction network maps a wiring diagram of cellular function, Science, vol.353, issue.6306, pp.1381-887, 2016.

D. A. Barbie, P. Tamayo, J. S. Boehm, S. Y. Kim, S. E. Moody et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, vol.462, issue.7269, pp.108-120, 2009.

Y. K. Wang, A. Bashashati, M. S. Anglesio, D. R. Cochrane, D. S. Grewal et al., Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes, Nat Genet, vol.49, issue.6, pp.856-64, 2017.

L. Chevalier, A. Billaud, S. Fronteau, J. Dauve, A. Patsouris et al., Somatic mRNA analysis of BRCA1 splice variants provides a direct theranostic impact on PARP inhibitors, Mol diagnosis Ther, vol.24, pp.233-276, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02512969

E. Khurana, Y. Fu, D. Chakravarty, F. Demichelis, M. A. Rubin et al., Role of non-coding sequence variants in cancer, Nat Rev Genet, vol.17, issue.2, pp.93-108, 2016.

E. Anastasiadou, L. S. Jacob, and F. J. Slack, Noncoding RNA networks in cancer, Nat Rev Cancer, vol.18, issue.1, pp.5-18, 2017.